Drugs / MART-1:27-35 peptide vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase not applicable1 trial | ||||||
| — | NCT00006243 | Oct 2000 → May 2006 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00091104 Background | Jul 2004 → Aug 2010 | cutaneous melanoma | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MART-1:27-35 peptide vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006243 ↗ |
| Modality | Vaccine | “MART-1:27-35 peptide vaccine” NCT00006243 ↗ |
| Route | Subcutaneous | “MART-1:27-35 peptide vaccine emulsified in incomplete Freund's adjuvant SC” NCT00091104 ↗ |